Printer Friendly

CYTRX CORPORATION INITIATES PRELIMINARY STUDY TO TEST THERMAX(TM) IN ALLERGIC SKIN REACTIONS

 NORCROSS, Ga., May 18 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR) announced today the initiation of a human clinical trial investigating the use of TherMax(TM), a proprietary dermatological agent, in experimentally induced allergic skin reactions.
 The study is expected to be completed in the summer and is part of the overall program to assess the anti-itching and anti-inflammatory properties of the drug.
 Jack J. Luchese, president and chief executive officer of the company, said, "We are pleased to begin this study with TherMax to further investigate
its safety and efficacy in dermatological conditions." Additional phase II studies in burns and for the treatment of other dermatological conditions are planned.
 CytRx Corporation is a biopharmaceutical company engaged in the research and development of therapeutics incorporating copolymers. The company is developing critical care pharmaceutical products intended for use in the treatment of vascular, cancer and infectious diseases as well as dermatological conditions. Vetlife(TM), Inc., a wholly owned subsidiary, is developing feed additives intended to enhance growth in food animals. Vaxcel, Inc., another wholly owned subsidiary, markets TiterMax(R), and is also developing the Optivax(TM) vaccine adjuvant technology.
 -0- 5/18/93
 /CONTACT: CytRx Corporation public relations, 404-368-9500/
 (CYTR)


CO: CytRx Corporation ST: Georgia IN: MTC SU:

BN-BR -- AT007 -- 9644 05/18/93 09:53 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 18, 1993
Words:214
Previous Article:PARKER & PARSLEY FILES LAWSUIT AGAINST LOUIS DREYFUS NATURAL GAS CORP. FOR TORTIOUS INTERFERENCE AND AGAINST GRAHAM ROYALTY, LTD. FOR BREACH OF...
Next Article:ROYAL CROWN COLA CO. SPONSORS UNLIMITED EXCITEMENT; BEGINS SECOND YEAR IN HYDROPLANE BOAT RACING
Topics:


Related Articles
CYTRX CORPORATION ANNOUNCES FILING OF IND APPLICATION FOR THERMAX(TM) GEL
CYTRX CORPORATION ANNOUNCES FIRST QUARTER RESULTS
CYTRX CORPORATION ANNOUNCES THE FORMATION OF VAXCEL(TM)
CYTRX CORPORATION ANNOUNCES 1992 RESULTS
CYTRX CORPORATION ANNOUNCES APPOINTMENT OF VICE PRESIDENT, MEDICAL & REGUALTORY AFFAIRS
CYTRX CORPORATION ANNOUNCES 1993 FIRST QUARTER RESULTS
CYTRX SAYS RHEOTHRX UNDER CONSIDERATION FOR ISIS-5 TRIAL
CYTRX CORPORATION ANNOUNCES 1993 NINE MONTH RESULTS
CYTRX CORPORATION LICENSES OPHTHALMIC PATENT FROM BRUJO CORPORATION
CYTRX ANNOUNCES COMMENCEMENT OF PHASE II THERMAX BURN TRIAL

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters